Alumni Ventures

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company founded in 2017 that specializes in developing and commercializing a wearable microfluidic sensing platform. This innovative technology analyzes small droplets of sweat directly from the skin to provide insights into health, hydration, and athletic performance. The platform is designed to measure various biomarkers, including proteomics and inflammatory markers, allowing for personalized management of health and nutrition. Epicore's approach leverages over two decades of research in microfluidics and soft materials conducted by leading experts at Northwestern University. By offering a non-invasive and cost-effective solution, Epicore aims to enhance athletic performance and improve overall health monitoring for users.

InGel Therapeutics is a platform technology company that develops stem cell therapeutics and biodegradable polymers. The company was founded in 2021 and is based in Cambridge, Massachusetts.

Modicus Prime specializes in developing advanced computer vision software and self-service artificial intelligence tools tailored for the life sciences sector. Their technology automates the analysis of biologics images, addressing challenges related to product quality failures that can result in significant costs, legal issues, and waste in research and manufacturing processes. The platform facilitates the integration of diverse life sciences data, enabling users to detect anomalies, monitor operations, and enhance decision-making. By allowing clients to execute cutting-edge research and production, train algorithms on specific data sets, and harness insights through self-service capabilities, Modicus Prime effectively addresses the evolving data challenges in the life sciences industry, including continuous manufacturing and intelligent monitoring.

Nanochon is focused on creating innovative implantable medical devices designed to address cartilage damage in joints. Utilizing advanced 3D printing techniques and a unique nanomaterial, the company aims to develop solutions that not only replace lost and damaged cartilage but also promote the growth of new tissue. This approach allows medical practitioners to access cost-effective and on-demand devices that enhance treatment outcomes, particularly for young and active patients suffering from knee injuries and diseases. Through its technology, Nanochon seeks to improve the overall quality of care in orthopedics.

YonedaLabs is a developer of AI-based software designed to assist chemists in optimizing various reaction parameters, including temperature, concentration, and catalysts. Their platform aims to enhance the efficiency of chemical laboratories by streamlining the process involved in drug and material production. By leveraging artificial intelligence, YonedaLabs enables businesses to accelerate their research and development efforts, ultimately improving outcomes in the field of chemistry.

Nectero Medical is a clinical-stage biotechnology company based in Dover, Delaware, that focuses on treating mid-sized abdominal aortic aneurysms. Founded in 2017, the company has developed an innovative treatment designed to stabilize the growth of aneurysms and prevent their rupture. This treatment delivers a compound containing a stabilizer agent directly to the aneurysm site, which helps inhibit further breakdown and strengthens the vessel wall. By providing a safer intervention option, Nectero Medical aims to enable patients to receive timely care, significantly delaying or preventing the need for major endovascular or surgical repair.

Century Health accelerates drug development and commercialization by applying AI to real-world data. It is far too slow today to answer critical questions because the richest clinical data is locked away in silos. Our platform does the heavy lifting to rapidly get you the insight you need, all while supporting the research community and protecting patient privacy.

Cyrus Biotechnology, Inc. specializes in developing software tools for protein structure prediction and design, aiming to enhance research in biotechnology and pharmaceuticals. The company's flagship product, Rosetta, allows for the design of biologically active proteins that can address critical health issues, such as brain cancer treatment and gluten breakdown in Celiac Disease patients. Additionally, Cyrus Bench offers an enterprise version of the Rosetta toolkit, equipped with a variety of bio-molecular computation tools. The company also provides Cyrus CryoEM services, which include advanced structure refinement and model building. Founded in 2014 and headquartered in Seattle, Washington, Cyrus Biotechnology serves a diverse clientele, including pharmaceutical companies, venture-backed startups, and mid-sized biotech firms focused on therapeutic discovery and industrial biotechnology innovation.

Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company founded in 2017 that specializes in developing and commercializing a wearable microfluidic sensing platform. This innovative technology analyzes small droplets of sweat directly from the skin to provide insights into health, hydration, and athletic performance. The platform is designed to measure various biomarkers, including proteomics and inflammatory markers, allowing for personalized management of health and nutrition. Epicore's approach leverages over two decades of research in microfluidics and soft materials conducted by leading experts at Northwestern University. By offering a non-invasive and cost-effective solution, Epicore aims to enhance athletic performance and improve overall health monitoring for users.

Granata Bio is a biotechnology company established in 2018, dedicated to identifying and developing therapeutics for fertility patients. The company focuses on creating a comprehensive portfolio of fertility treatments and possesses expertise in commercialization, late-stage clinical trials, and regulatory development. Granata Bio aims to address significant challenges faced by medical professionals in the field of fertility treatment. Recently, the company announced a collaboration with IBSA Institut Biochimique to co-develop a novel subcutaneous progesterone solution, further enhancing its commitment to advancing fertility care.

Anthology is an evolution company that generates diverse genomes to scale and digitalize biomanufacturing.

Featureform develops machine learning tools specifically for pharmaceutical and biotechnology companies. The company offers an open-source virtual feature store that enables data scientists to define, manage, and serve machine learning features throughout their organizations. Its platform provides a unified interface to connect, transform, and join both streaming and batch data. Featureform facilitates the discovery and integration of features created by various teams, allowing them to share and enhance their models. Additionally, the platform includes capabilities to monitor and analyze features, as well as to freeze them, which allows teams to concentrate on building models to support their data pipelines effectively.

Capra Biosciences is a biotechnology company focused on the efficient and low-carbon production of everyday chemicals through innovative bioreactor technology. The company has developed a biofilm bioreactor platform that aims to enhance the bio-manufacturing process by significantly reducing downstream processing requirements and associated costs. This technology facilitates the production of a variety of bio-based chemicals, including hydrophobic products like retinol and performance lubricants, thus advancing sustainable practices in the chemical industry.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

Jona is a technology startup focused on leveraging artificial intelligence to explore the relationship between the microbiome and overall health. The company has developed an advanced microbiome profiling platform that utilizes deep metagenomics technology to analyze a wide range of microorganisms, including bacteria, fungi, viruses, and protists. This analysis creates a comprehensive map that links these microorganisms to various health conditions, symptoms, and food sensitivities. By interpreting microbiome test results, Jona aims to empower individuals to proactively manage their health through informed recommendations on diet, exercise, sleep, and other treatments, addressing the growing prevalence of chronic illnesses.

Ummino is a company based in Raleigh, North Carolina, that specializes in precision fermentation technology for the fortified food and beverage sectors. Founded in 2019, Ummino’s innovative technology allows customers to convert common ingredients into high-value functional foods by unlocking rare compounds and enhancing taste and nutritional value. The company's focus on optimizing these properties positions it to significantly impact the food industry, particularly in the realm of functional and fortified products.

Eigen Therapeutics is a biotechnology company on a mission to make therapies that make cancer easier to find and eliminate. Eigen is focused on the development of “priming” therapies, therapies that help targeted therapies reach their full potential by addressing cancer heterogeneity, making cancer cells more vulnerable and/or making healthy cells more resilient to treatment. Eigen is building a high-throughput discovery platform to explore the space of priming therapies, leveraging proprietary machine learning algorithms to discover novel associations, new classes of drugs, and new potential therapies that change a cell's state to make it more vulnerable to a targeted therapy. The Eigen platform represents the intersection of biology and engineering, and includes robotic systems, laboratory operations software, and machine learning analysis pipelines—all developed in-house—with the ultimate goal of saving more lives.

TFC Therapeutics is a biotechnology company focused on developing innovative biologics aimed at addressing key drivers of cancer recurrence and metastasis. The company’s technology utilizes monoclonal antibodies that specifically bind to receptors on the surface of tumor-initiating cells (TMH cells). This binding action activates the immune system to target and destroy these cells, offering the potential for new cancer treatments. By concentrating on the elimination of TMH cells, TFC Therapeutics seeks to provide effective solutions for improving patient outcomes in cancer care.

VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, it specializes in the development of bioresorbable smart polymers designed to enhance vascular surgery outcomes. The company’s primary product, SelfWrap, is a perivascular wrap that functions as an external stent, providing mechanical support to veins and promoting outward growth. This innovative technology aims to reduce complications at the vein-artery junction in dialysis patients, particularly by minimizing vein collapse and improving the usability of arteriovenous fistulas (AVF). By utilizing a new class of shape-memory polymers that do not require sutures, VenoStent's approach reduces surgery time and lowers the risk of infection, ultimately enhancing the quality and length of life for patients with chronic kidney disease undergoing hemodialysis.

Ossium Health, Inc. is engaged in the development and manufacturing of cell therapy products aimed at treating leukemia, other blood cancers, and tissue damage, as well as addressing radiation poisoning. The company offers a range of innovative therapies, including HPC, Marrow, which features HLA-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients; Chimera, which enhances organ transplantation; and Chymalis, composed of mesenchymal stem cells that promote the healing of damaged bone and muscle tissue. Additionally, Ossium provides bone marrow cells for research purposes in oncology and immunology. Founded in 2016 and headquartered in San Francisco, California, Ossium Health focuses on improving health outcomes and longevity through advanced bioengineering techniques.

MEND is a life sciences company dedicated to advancing health and recovery through targeted clinical nutrition and medical food interventions. The company focuses on researching and developing products that enhance patient outcomes in various contexts, including injury recovery, surgical recovery, aging, and physical performance. MEND's solutions have been widely adopted by hospitals, health systems, and professional sports teams across major leagues, as well as by the elite forces of the US Military. Through its commitment to ongoing research and development, MEND aims to empower caregivers and improve health outcomes for individuals facing diverse health challenges.

Synteny.Ai Syntney decodes the signals of immune repertoires to help biotech research and pharma companies with disease discoveries.

Dimension Inx Corp. focuses on designing and developing three-dimensional (3D) printable materials and painted objects for research and commercial applications. The company specializes in creating regenerative microenvironments that aid the body in self-healing. Its biomaterials platform incorporates a complex interplay of material composition, microstructure, and microarchitecture to enhance biofunctionality. Dimension Inx offers a range of products, including Hyperelastic Bone for bone regeneration, 3D printable elastomers, bioactive ceramics, and solutions for soft tissue regeneration. Founded in 2016 and based in Chicago, Illinois, the company aims to provide innovative therapeutic products that restore tissue and organ function, potentially reducing the need for organ transplantation through advanced bio-fabrication processes.

Featureform develops machine learning tools specifically for pharmaceutical and biotechnology companies. The company offers an open-source virtual feature store that enables data scientists to define, manage, and serve machine learning features throughout their organizations. Its platform provides a unified interface to connect, transform, and join both streaming and batch data. Featureform facilitates the discovery and integration of features created by various teams, allowing them to share and enhance their models. Additionally, the platform includes capabilities to monitor and analyze features, as well as to freeze them, which allows teams to concentrate on building models to support their data pipelines effectively.

Precision Neuroscience is a company focused on developing advanced brain-computer interface technology aimed at offering innovative treatments for the approximately one billion individuals worldwide affected by neurological disorders. Founded in 2021 and based in New York, the company's technology is characterized by its minimally invasive design, safety for removal, and capacity for processing substantial data. This platform enables medical professionals to establish a direct connection between the human brain and artificial intelligence, potentially transforming the landscape of neurological care.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.

Modicus Prime specializes in developing advanced computer vision software and self-service artificial intelligence tools tailored for the life sciences sector. Their technology automates the analysis of biologics images, addressing challenges related to product quality failures that can result in significant costs, legal issues, and waste in research and manufacturing processes. The platform facilitates the integration of diverse life sciences data, enabling users to detect anomalies, monitor operations, and enhance decision-making. By allowing clients to execute cutting-edge research and production, train algorithms on specific data sets, and harness insights through self-service capabilities, Modicus Prime effectively addresses the evolving data challenges in the life sciences industry, including continuous manufacturing and intelligent monitoring.

Eigen Therapeutics is a biotechnology company on a mission to make therapies that make cancer easier to find and eliminate. Eigen is focused on the development of “priming” therapies, therapies that help targeted therapies reach their full potential by addressing cancer heterogeneity, making cancer cells more vulnerable and/or making healthy cells more resilient to treatment. Eigen is building a high-throughput discovery platform to explore the space of priming therapies, leveraging proprietary machine learning algorithms to discover novel associations, new classes of drugs, and new potential therapies that change a cell's state to make it more vulnerable to a targeted therapy. The Eigen platform represents the intersection of biology and engineering, and includes robotic systems, laboratory operations software, and machine learning analysis pipelines—all developed in-house—with the ultimate goal of saving more lives.

Axoft offers a bioinspired, scalable implant that promotes long-term communication with the nervous system, transforming clinical outcomes, individual health, and the human experience.

SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed. The company provides an injectable biodegradable hydrogel that allows for the prolonged, localized release of most cancer immunotherapy on the website of surgical tumor resection by focusing the dose at the right place and right time.

Nanopath Inc. is a molecular diagnostics company focused on enhancing women's health through rapid and precise testing. By utilizing advancements in bioengineering and nanotechnology, the company specializes in the sensitive detection of viral, bacterial, and fungal pathogens without relying on nucleic acid amplification techniques. This innovative approach allows for the delivery of granular and clinically actionable information, thereby improving traditional testing methodologies and enabling healthcare providers to make informed decisions more swiftly.

Magnetic Insight, Inc. specializes in magnetic particle imaging (MPI), an innovative imaging technology that utilizes iron oxide nanoparticle tracers and time-varying magnetic fields. The company has developed several products, including the MOMENTUM imager, a pre-clinical MPI solution that produces high-quality images through advanced magnet geometry and a proprietary reconstruction process. Additionally, Magnetic Insight offers VivoTrax, a nanoparticle designed for cell tracking and as a blood pool agent in pre-clinical studies, and Hyper, an add-on module for the MOMENTUM system that assists in identifying treatment targets and administering localized magnetic hyperthermia. Another product, Relax, serves as a particle relaxometry module. Founded in 2012 and headquartered in Alameda, California, Magnetic Insight aims to enhance preclinical diagnostic research by enabling quantitative cell tracking, imaging of vascular functions, and visualization of various biological processes, thereby addressing challenges in clinical and translational research.

Swing is creating the next generation of safe and effective digital therapeutics for people with chronic conditions. Our team of passionate scientists, clinicians, and technologists are partnering with some of the world’s top researchers to develop evidence-based transformative digital treatments. Swing’s solutions empower patients to regain control of their illnesses. Together, we are helping people achieve improved health so that they can lead more joyful, vibrant lives.

SCiFi Foods is a food technology company focused on producing cultivated meat that combines lab-grown beef cells with plant-based ingredients to create burgers that closely replicate the taste of traditional beef. The company aims to provide a sustainable and ethical alternative to conventional meat by utilizing bioengineering techniques to grow meat cells without relying on animal farming. SCiFi Foods has achieved significant advancements, including the successful growth of beef cells in suspension, which has the potential to drastically reduce production costs. Founded by CEO Joshua March and CTO Kasia Gora, PhD, the company has attracted $29 million in funding from prominent investors, positioning it for future growth in the alternative protein market.

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

Unicorn Biotechnologies is developing a next-generation biomanufacturing platform to power the cell-based manufacturing revolution, starting with cultivated meat. By providing a clear path to affordably and rapidly scale cultivated meat, we will improve human and planetary health and drive the transition to animal-free agriculture.

American Gene Technologies (AGT) specializes in developing innovative gene therapies aimed at curing serious diseases, including infectious diseases, cancers, and inherited disorders. The company is advancing its proprietary gene-delivery platform, which is backed by multiple patents, including those for its AGT103-T cell product designed to functionally cure HIV. AGT is also focused on a unique immuno-oncology approach that stimulates gamma-delta T cells to target various solid tumors. Additionally, the company has developed a synthetic gene to provide effective treatments for Phenylketonuria (PKU). AGT’s clinical trial for an HIV cure has the potential to not only address a significant public health challenge but also validate its technology platform for treating a variety of diseases.

Concerto Biosciences specializes in rebuilding microbial communities to enhance human health and environmental sustainability. The company has developed an ultra-high-throughput platform capable of measuring millions of microbial interactions, enabling the mapping of complex inter-species networks that dictate community behavior. This innovation allows Concerto to create "ensembles," which are specific combinations of microbes that collaboratively promote the recovery of damaged microbial ecosystems. By focusing on these microbial ensembles, Concerto aims to address critical global issues across various sectors, including agriculture, healthcare, and industry. The company's pioneering work positions it as a leader in the development of microbial solutions, fundamentally changing how humanity interacts with microbial life.

Satellite Bio is a company that specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It is dedicated to developing a therapeutic platform aimed at creating innovative cell therapies to address complex diseases. The company’s primary focus is on the design and implementation of proprietary, off-the-shelf, implantable satellite organs, which serve as living therapeutic solutions. These satellite organs are intended to improve the lives of millions of patients suffering from serious health conditions.

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company founded in 2017 that specializes in developing and commercializing a wearable microfluidic sensing platform. This innovative technology analyzes small droplets of sweat directly from the skin to provide insights into health, hydration, and athletic performance. The platform is designed to measure various biomarkers, including proteomics and inflammatory markers, allowing for personalized management of health and nutrition. Epicore's approach leverages over two decades of research in microfluidics and soft materials conducted by leading experts at Northwestern University. By offering a non-invasive and cost-effective solution, Epicore aims to enhance athletic performance and improve overall health monitoring for users.

Verge Genomics is a biotechnology company focused on transforming drug discovery for neurodegenerative diseases through the application of artificial intelligence. Founded by experts in machine learning and seasoned drug developers in neuroscience, the company aims to leverage advances in computational genomics and insights into brain science to identify promising therapeutic targets. Its drug discovery platform utilizes machine learning algorithms to analyze large datasets, enabling the identification of effective drugs and accelerating the development of life-saving treatments. By improving the efficiency of the drug development process, Verge Genomics seeks to enhance patient outcomes and reduce the overall costs associated with pharmaceutical development.

Droplette Inc., founded in 2017 and based in Boston, Massachusetts, specializes in the development of a needle-free skincare device that utilizes a patent-pending transdermal delivery system. This innovative technology allows for the delivery of drugs up to 60% larger than traditional treatments, penetrating deeply into the skin over large surface areas. The device is designed to be painless, contact-free, and portable, generating no disposables. Initially aimed at delivering antibiotics for serious skin conditions such as ulcers and infections, Droplette also envisions future applications for localized delivery of chemotherapeutics for skin cancer and anti-aging treatments. By enabling effective skincare without harmful chemicals, Droplette aims to transform skin health through scientific advancement.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

Cellibre is a cellular agriculture company that turns cells into specialized, sustainable factories for the manufacture of globally significant products at scale.

Olaris is dedicated to transforming disease diagnosis and treatment through its innovative CEREBRO platform, which integrates metabolomics and machine learning. This platform focuses on the Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes, enabling the identification of biomarkers that can optimize patient treatment. By developing the myOLARIS™ precision diagnostics, Olaris aims to match the right drug to the right patient, enhancing clinical outcomes while minimizing adverse events. Founded in 2013 and headquartered in Framingham, Massachusetts, the company collaborates with healthcare providers to improve patient care through advanced diagnostic solutions.

Cyrus Biotechnology, Inc. specializes in developing software tools for protein structure prediction and design, aiming to enhance research in biotechnology and pharmaceuticals. The company's flagship product, Rosetta, allows for the design of biologically active proteins that can address critical health issues, such as brain cancer treatment and gluten breakdown in Celiac Disease patients. Additionally, Cyrus Bench offers an enterprise version of the Rosetta toolkit, equipped with a variety of bio-molecular computation tools. The company also provides Cyrus CryoEM services, which include advanced structure refinement and model building. Founded in 2014 and headquartered in Seattle, Washington, Cyrus Biotechnology serves a diverse clientele, including pharmaceutical companies, venture-backed startups, and mid-sized biotech firms focused on therapeutic discovery and industrial biotechnology innovation.

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

Strateos is a company that specializes in automating laboratory processes in chemistry, biology, and tissue analysis through its advanced robotic cloud laboratory platform. By integrating cutting-edge robotics with sophisticated software for imaging and analytics, Strateos provides pharmaceutical partners with the tools to accelerate drug discovery and development. The company emerged from a merger between Transcriptic, which pioneered on-demand robotic lab services, and 3Scan, known for its automation and machine learning capabilities in tissue analysis. Strateos aims to streamline the drug discovery process by offering a comprehensive suite of technologies that transform life science methods into data-driven solutions. This approach not only enhances productivity and efficiency but also redefines the traditional research model, making it more accessible and effective for scientists. Through its innovative platform, Strateos positions itself as a valuable partner in the life sciences sector, focusing on delivering significant time and cost savings in the drug development process.

miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.

Prima is a wellness brand that specializes in plant-based skincare, body care, and supplements, primarily utilizing organic hemp CBD and functional botanicals. The company is dedicated to addressing stress and other health issues at their source through scientifically backed products made from clinically studied ingredients. Emphasizing sustainability and transparency, Prima maintains high standards of purity and potency, and it is recognized as Climate Neutral Certified, Plastic Neutral Certified, and a certified B Corp. Based in Santa Monica, California, Prima operates as a privately held Public Benefit Corporation, focusing on the intersection of science, nature, and health to enhance consumer well-being and foster social impact through its innovative offerings.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.

InteRNA Technologies B.V. is a biotechnology company focused on the development of microRNA (miRNA)-based therapeutics for cancer treatment. The company's innovative approach leverages the unique properties of miRNAs to target previously undruggable pathways involved in cancer initiation, progression, and metastasis. By utilizing advanced techniques such as massively parallel sequencing and proprietary bioinformatics, InteRNA analyzes and validates miRNA sequences to enhance drug efficacy and reduce resistance to existing therapies. Founded in 2006, the company operates from Nijmegen, the Netherlands, and has a dedicated research and development center in Utrecht. Recently, InteRNA has secured additional equity financing to advance its lead program for melanoma treatment, demonstrating its commitment to developing novel solutions in oncology.

Concerto Biosciences specializes in rebuilding microbial communities to enhance human health and environmental sustainability. The company has developed an ultra-high-throughput platform capable of measuring millions of microbial interactions, enabling the mapping of complex inter-species networks that dictate community behavior. This innovation allows Concerto to create "ensembles," which are specific combinations of microbes that collaboratively promote the recovery of damaged microbial ecosystems. By focusing on these microbial ensembles, Concerto aims to address critical global issues across various sectors, including agriculture, healthcare, and industry. The company's pioneering work positions it as a leader in the development of microbial solutions, fundamentally changing how humanity interacts with microbial life.

Cultured Decadence is a startup based in Madison, Wisconsin, focused on cellular aquaculture to produce crustacean products. Founded in 2020, the company employs innovative cell culture and tissue engineering techniques to create lobster and crab meat directly from the animals' cells, eliminating shell, organs, and waste. This approach addresses the increasing global demand for sustainable and nutritious seafood, offering a more environmentally friendly alternative to traditional fishing methods.

Unlearn.AI, Inc. is a biotechnology company that specializes in developing software tools for clinical research, focusing on improving diagnosis and treatment processes. Based in San Francisco, the company offers solutions such as Clinical Trial Design, which helps define inclusion criteria, endpoints, and study sizes; Synthetic Control Arms, which reduce or eliminate the necessity for concurrent control groups; and Subgroup Analysis, which identifies specific patient subgroups within trial results. Unlearn.AI has pioneered the TwinRCT solution, a digital twin service that leverages machine learning to enhance the efficiency and success rates of clinical trials. This innovative approach creates a prognostic digital twin for each patient, allowing for more precise estimations of treatment effects based on historical data. By integrating machine learning and biostatistics, Unlearn.AI aims to accelerate the clinical trial process, benefiting both patients and pharmaceutical sponsors.

Arable is a developer of an integrated system for agriculture that helps digitize and optimize decisions from seed breeding to food production. The platform measures everything that matters to the crop, from the weather to the soil, to the plant itself by the use of a unique set of spectral and thermal sensors. This enables Arable to observe a crop’s development through the season and determine the onset of stress due to a lack of water or nutrients. Its integrated hardware, agronomic modeling, and software suite is enabling farmers, agronomists, researchers, processors, and food companies to understand the crop system at the plant, field, and region level, which helps to reduce risk, improve productivity, and optimize for sustainability. Arable received recognition, including the Irrigation Association’s Best New Product of 2018, Plug & Play’s Top 10 Ag Tech Companies to Watch in 2019, and THRIVE’s Top 50 Companies for 2020 awards.

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

SCiFi Foods is a food technology company focused on producing cultivated meat that combines lab-grown beef cells with plant-based ingredients to create burgers that closely replicate the taste of traditional beef. The company aims to provide a sustainable and ethical alternative to conventional meat by utilizing bioengineering techniques to grow meat cells without relying on animal farming. SCiFi Foods has achieved significant advancements, including the successful growth of beef cells in suspension, which has the potential to drastically reduce production costs. Founded by CEO Joshua March and CTO Kasia Gora, PhD, the company has attracted $29 million in funding from prominent investors, positioning it for future growth in the alternative protein market.

Unlearn.AI, Inc. is a biotechnology company that specializes in developing software tools for clinical research, focusing on improving diagnosis and treatment processes. Based in San Francisco, the company offers solutions such as Clinical Trial Design, which helps define inclusion criteria, endpoints, and study sizes; Synthetic Control Arms, which reduce or eliminate the necessity for concurrent control groups; and Subgroup Analysis, which identifies specific patient subgroups within trial results. Unlearn.AI has pioneered the TwinRCT solution, a digital twin service that leverages machine learning to enhance the efficiency and success rates of clinical trials. This innovative approach creates a prognostic digital twin for each patient, allowing for more precise estimations of treatment effects based on historical data. By integrating machine learning and biostatistics, Unlearn.AI aims to accelerate the clinical trial process, benefiting both patients and pharmaceutical sponsors.

Endless West is a beverage startup focused on producing innovative wines and spirits using scientific methods. The company creates its products at a molecular level by extracting flavor, aroma, and color molecules from various plants and substances, eliminating the need for traditional ingredients like grapes and yeast. This approach allows Endless West to craft sustainable beverages without fermentation, significantly reducing the resources required for production, such as wood, water, and land. Its flagship product, Glyph, is an aged-style spirit that showcases this pioneering technique, offering consumers a unique drinking experience while promoting environmental sustainability.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company specializes in developing gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company is committed to advancing these therapeutics to ensure they are safe and effective, with the goal of significantly improving the lives of individuals affected by viral infections worldwide.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

Notable Labs, Inc. is a clinical-stage company based in Foster City, California, focused on developing personalized testing services for cancer patients, particularly those with brain cancer. The company operates a platform that conducts drug combination experiments on tumors, providing actionable reports to doctors. These reports prioritize combinations of FDA-approved treatments that can be immediately prescribed, avoiding the need for lengthy clinical trials. Notable Labs utilizes its proprietary Predictive Precision Medicines Platform to bio-simulate cancer treatments, predicting patient responses to specific therapies. This approach aims to streamline the identification of patients likely to benefit from targeted treatments, thereby enhancing therapeutic development for cancer care.

miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.

Olaris is dedicated to transforming disease diagnosis and treatment through its innovative CEREBRO platform, which integrates metabolomics and machine learning. This platform focuses on the Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes, enabling the identification of biomarkers that can optimize patient treatment. By developing the myOLARIS™ precision diagnostics, Olaris aims to match the right drug to the right patient, enhancing clinical outcomes while minimizing adverse events. Founded in 2013 and headquartered in Framingham, Massachusetts, the company collaborates with healthcare providers to improve patient care through advanced diagnostic solutions.

E25Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing rapid diagnostic tests for epidemic fever viruses, including dengue, chikungunya, and Zika. Founded in 2018, the company specializes in paper-based diagnostic systems that enable swift detection of viral antigens produced during infections. Its innovative platform allows for real-time data reporting through a mobile application, which captures results along with information on test timing and location. This approach aims to facilitate epidemiologic predictions and disease mapping, ultimately assisting governments and health organizations in managing outbreaks effectively and preventing public health crises. E25Bio's solutions are designed to provide affordable and timely diagnostics at the point of care.

Motif develops plant-based food products designed to produce healthy food using genetic engineering and fermentation. Their food technologies enable CPG companies to develop plant-based alternatives that have the same meaty taste, appearance, and texture as their animal counterparts. They offer bioprocessing services, finished products, and food services.

Emerald Cloud Lab, Inc. is a biotechnology company based in South San Francisco, California, that develops an innovative life sciences laboratory designed to streamline and enhance scientific research. Founded in 2010 by two scientists, the company aims to address the challenges of rising research and development costs in the pharmaceutical industry by automating and optimizing laboratory workflows. The Emerald Cloud Laboratory provides a comprehensive facility that manages various aspects of laboratory operations, including method design, materials logistics, sample preparation, instrument operation, data acquisition, analysis, and waste disposal. This approach allows researchers to focus on designing experiments and analyzing results rather than on routine tasks, thereby accelerating the pace of innovation in life sciences. Emerald's commitment to improving laboratory efficiency reflects a vision of driving significant advancements in research and development akin to the technological shifts seen in the semiconductor industry.

Ceradis develops and markets innovative environmental friendly solutions for plant nutrition, crop protection and formulation technology. Ceradis products have a patented formulation, optimal activity of the ingredients and excellent handling characteristics for the end-users.

Seed Health is a biotechnology company focused on developing health supplements that utilize bacteria to enhance human and environmental health. The company collaborates with academic researchers to advance innovations in microbial sciences, offering a range of products that combine probiotics and prebiotics. These supplements are designed to provide systemic benefits, addressing areas such as digestive health, skin health, heart health, and micronutrient synthesis. Through its work, Seed Health aims to deliver live biotherapeutics that support overall well-being and contribute to scientific advancements in the field.

StemoniX Inc. is a biotechnology company specializing in stem cell technologies to enhance drug discovery and personalized medicine. Founded in 2014 and headquartered in Minneapolis, Minnesota, with an additional office in La Jolla, California, StemoniX offers a platform that focuses on the 3-D printing of stem-cell derived human tissues. This innovative approach allows for the creation of custom drug discovery models and facilitates the development of living cells in larger formats, addressing various medical conditions such as heart disease, dementia, breast cancer, autism, and ALS. The company's platform also operationalizes human induced pluripotent stem cell (iPSC) disease models for high-throughput screening, improving the research process for neurotoxicity and other drug screening efforts.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Mitra Biotech is a biotechnology company that specializes in providing personalized cancer treatment. It aims on developing new technologies that surpass existing biomarker-guided strategies for cancer treatment selection, expanding access to truly personalized medicine, and enhancing the clinical management of cancer. The company was founded in 2010 and headquartered in Woburn, Massachusetts.

American Gene Technologies (AGT) specializes in developing innovative gene therapies aimed at curing serious diseases, including infectious diseases, cancers, and inherited disorders. The company is advancing its proprietary gene-delivery platform, which is backed by multiple patents, including those for its AGT103-T cell product designed to functionally cure HIV. AGT is also focused on a unique immuno-oncology approach that stimulates gamma-delta T cells to target various solid tumors. Additionally, the company has developed a synthetic gene to provide effective treatments for Phenylketonuria (PKU). AGT’s clinical trial for an HIV cure has the potential to not only address a significant public health challenge but also validate its technology platform for treating a variety of diseases.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Seed develops clinically-studied probiotics to impact human and planetary health.

Equillium Inc is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory disorders that have significant unmet medical needs. The company's leading product candidate, EQ001, is a first-in-class monoclonal antibody that specifically targets the immune checkpoint receptor CD6, which is crucial in regulating effector T cell activity associated with various immuno-inflammatory diseases, including graft-versus-host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis. In addition to EQ001, Equillium's pipeline includes itolizumab, an antibody targeting the CD6-ALCAM pathway, which is undergoing Phase 3 trials for acute graft-versus-host disease and Phase 1b trials for lupus nephritis. The company is also advancing EQ101, a cytokine inhibitor aimed at IL-2, IL-9, and IL-15, which is poised to enter Phase 2 studies for alopecia areata, and EQ102, another cytokine inhibitor that targets IL-15 and IL-21, which is ready for clinical development.

Manus Bio Inc. specializes in recreating plant processes within microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company focuses on converting sugar sources into a variety of applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. By integrating metabolic engineering, protein engineering, and systems biology, Manus Bio develops microbes that efficiently manufacture complex and bioactive natural products. The company operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. Formerly known as Manus Biosynthesis, Inc., the company adopted its current name in June 2018.

Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Celularity is a clinical-stage biotechnology company focused on advancing cellular medicine through the development of off-the-shelf placental-derived allogeneic cell therapies. Its product pipeline includes unmodified and genetically modified natural killer (NK) cells, CAR-engineered T cells, and mesenchymal-like adherent stromal cells. The company targets various health conditions, including cancer, immunologic disorders, infectious diseases, and degenerative illnesses. Celularity leverages the unique biology of the placenta, aiming to create effective and accessible therapies to address significant unmet medical needs. In addition to its cell therapy initiatives, Celularity operates a bio-banking segment, which contributes substantially to its revenue.

Harbor MedTech, Inc. is a regenerative medicine company based in Irvine, California, specializing in the development and commercialization of tissue regeneration products. Founded in 2010, the company offers a range of solutions for chronic wounds, hernia and joint repair, and soft tissue reinforcement. Notable products include Architect, an extracellular collagen matrix designed for managing various skin wounds, and EPMatrix, a collagen scaffold aimed at soft tissue repair. The company's innovative BriDGE platform enables the creation of advanced therapies for applications including breast reconstruction, Achilles tendon repair, and rotator cuff repair, as well as other surgical needs in dermatology and general surgery. Harbor MedTech is also engaged in a strategic partnership with Edwards Lifesciences to enhance its product offerings and market reach.

Manus Bio Inc. specializes in recreating plant processes within microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company focuses on converting sugar sources into a variety of applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. By integrating metabolic engineering, protein engineering, and systems biology, Manus Bio develops microbes that efficiently manufacture complex and bioactive natural products. The company operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. Formerly known as Manus Biosynthesis, Inc., the company adopted its current name in June 2018.

NewLeaf Symbiotics is an agriculture technology company based in Saint Louis, Missouri, that specializes in the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on natural bacteria, particularly pink pigmented facultative methylotrophs, which are utilized in various agricultural products for row crops, vegetables, fruits, and flowers. Through laboratory, greenhouse, and field trials, NewLeaf Symbiotics aims to provide sustainable agricultural solutions that assist farmers in combating plant diseases and improving overall agricultural productivity. Founded in 2011 and originally known as TrophoMax, LLC, the company rebranded to its current name in 2012.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for solid tumors and hematological malignancies. Founded in 2014 and based in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to identify and develop innovative antibody therapeutics. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase I clinical trials. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, and has completed a Phase 1 dose escalation study. Additionally, CTX-8371, another bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Compass Therapeutics aims to engage the immune system effectively to advance its therapeutic offerings.

Florence Healthcare, Inc. is a company that specializes in developing software tools for managing and monitoring clinical trial data. Founded in 2014 and headquartered in Atlanta, Georgia, the company offers the CloudBinder Suite, which streamlines data management for clinical sites and facilitates centralized and remote monitoring for sponsors. Additionally, Florence provides CloudBinder Redaction software, allowing clients to easily upload documents, redact patient information, and share these documents with sponsors and contract research organizations (CROs). The company's solutions are designed to replace traditional paper-based processes, advancing clinical research for pharmaceutical, biotech, and device sponsorship companies.

ISOThrive is a developer of microbiome product intended to support human and animal health. The company's product is a zero-calorie prebiotic soluble carbohydrate fiber made from plants and fermented vegetables designed by nature to feed the beneficial bacteria in the digestive system without adding any calories to the diet, enabling consumers to maximize health and wellness for nourishing and strengthening the body.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for solid tumors and hematological malignancies. Founded in 2014 and based in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to identify and develop innovative antibody therapeutics. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase I clinical trials. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, and has completed a Phase 1 dose escalation study. Additionally, CTX-8371, another bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Compass Therapeutics aims to engage the immune system effectively to advance its therapeutic offerings.